CareRx Corporation
Is CareRx Corporation (CRRX) halal?
CareRx Corporation (TSX: CRRX) is Canada's leading provider of pharmacy services to seniors in long-term care homes, retirement communities and assisted-living facilities — serving ~91,719 average beds in Q2 2026 through a national network of pharmacy fulfilment centres, medication management, multi-dose compliance packaging, and medical supplies via Revicare. The business passes the business gate with no haram segments identified. Interest-bearing debt of ~C$76.3M at June 30, 2026 is ~36.1% of a ~C$211.7M market cap, over the ~33% AAOIFI ceiling. Interest income is ~0.06% of revenue (passes); cash of ~C$9.6M (~4.5% of market cap) passes. Result: FAIL on the debt gate. Data from Q2 2026 results, screened October 1, 2026.
Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.
The two-gate Shariah screen
Every screener on this site runs the same two gates: first, the business must be halal (no conventional insurance, banking, alcohol, gambling, weapons manufacturing, and the like); second, the financial ratios must clear (debt under roughly 33% of market cap, non-compliant income under roughly 5%).
Gate one: the business — passes
CareRx is a single-reportable-segment institutional pharmacy business (H1 2026 revenue mix: 78% sale of goods, 19% capitated pharmacy service fees, 3% other pharmacy services; 64% Eastern Canada / 36% Western Canada). No banking/insurance, alcohol, gambling, weapons, pork, or conventional-finance activities are disclosed in filings or press releases — no haram segments identified. The business gate passes. (Corporate notes: TSX accepted its Normal Course Issuer Bid renewal on September 15, 2026; 63,429,589 shares outstanding as of September 3, 2026; quarterly dividend raised 10% to C$0.022/share, payable October 8, 2026.)
Gate two: the ratios — debt fails
- Interest-bearing debt: about C$76.3M at June 30, 2026 — borrowings (term loan and other) C$38.7M (current C$5.3M + non-current C$33.4M) plus lease liabilities C$37.7M (current C$2.7M + non-current C$35.0M). Figures in thousands in the filings.
- Market cap: about C$211.7M (63,514,039 shares outstanding at June 30, 2026 + 1,603,769 RSUs/DSUs + 433,805 stock options = 65,551,613 fully diluted × C$3.23, TSX, October 1, 2026).
- Debt ÷ market cap: C$76.3M ÷ C$211.7M = ~36.1% — over the ~33% AAOIFI ceiling (fails). Sensitivity note: borrowings alone are only ~18.3% of market cap, so the FAIL hinges on counting lease liabilities as debt — applied consistently across all screeners on this site.
- Interest income ÷ revenue: ~C$112k for six months ended June 30, 2026 (Note 13, "Finance costs, net"), roughly ~C$224k annualized vs ~C$375M annualized revenue (H1 C$187.5M × 2) = ~0.06% — far under the ~5% ceiling (passes). Interest income is a separately disclosed line.
- Cash ÷ market cap: C$9.6M of cash and cash equivalents at June 30, 2026 (restricted cash C$0.5M excluded; no short-term securities line) — about 4.5% of market cap, under the ~33% ceiling (passes).
The FAIL comes from the debt gate alone; it is close — 36.1% against a ~33% ceiling.
What other screeners say
- Zoya: screening data is app-gated; no public CRRX page found via web search, so coverage cannot be confirmed or denied. Musaffa: publishes per-stock pages for TSX tickers under the .CA pattern (e.g. GTEX.CA), but musaffa.com/stock/CRRX.CA/ returns a 404 and site search returns zero results — not covered. ShariaPortfolio: a licensed portfolio-management firm with no public per-stock screener database — no coverage. Our screener reports its own figure-by-figure analysis above.
The bottom line
This screener gives CareRx Corporation (TSX: CRRX) a FAIL. The senior-care pharmacy business passes the business gate, interest income (~0.06% of revenue) and cash (~4.5% of market cap) both pass — but interest-bearing debt of ~C$76.3M is ~36.1% of a ~C$211.7M market cap, over the ~33% ceiling. It is close enough that deleveraging or share-price appreciation could flip it next quarter. Snapshot dated October 1, 2026; re-checked quarterly after earnings.
BDS screen
Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.
No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).
Moral screen
Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.
- Israeli military business
- No findings published.
- US military business
- No findings published.
- Weapons manufacturing & arms trade
- No findings published.
Halal alternatives in this sector
CRRX did not pass the screen. These companies in the same sector passed:
- Cipher Pharmaceuticals Inc. PASS
- Extendicare Inc. PASS
- Knight Therapeutics Inc. PASS
Sources
- CareRx Corporation Q2 2026 unaudited interim consolidated financial statements (July 29, 2026) — borrowings C$38,666k, lease liabilities C$37,669k, cash and cash equivalents C$9,574k; Note 13 "Finance costs, net": interest income C$112k (six months ended June 30, 2026); revenue C$187,494k (H1 2026); 63,514,039 shares outstanding at June 30, 2026; 1,603,769 RSUs/DSUs; 433,805 stock options; ~91,719 average beds serviced; H1 2026 revenue mix 78%/19%/3%.
- CareRx NCIB renewal press release (Newsfile, September 15, 2026) — TSX acceptance, 63,429,589 shares outstanding as of September 3, 2026; quarterly dividend raised 10% to C$0.022/share.
- CareRx Q2 2026 results press release (August 2026) — via StockTitan.
- Market data: TSX:CRRX C$3.23, 65,551,613 fully diluted shares — market cap ~C$211.7M on October 1, 2026 (Finnhub; Barchart and StockAnalysis cross-checks).
- Third-party coverage checks (October 1, 2026): no public Zoya CRRX page; Musaffa CRRX.CA 404 (meaningful against the .CA pattern); ShariaPortfolio has no public screener database.
Related screeners
Frequently asked questions
Is CareRx (CRRX) halal?
Our screener gives CareRx Corporation a FAIL screening result. The business — Canada's leading pharmacy services provider for seniors in long-term care and retirement homes, serving ~91,719 average beds in Q2 2026 — passes the business gate with no haram segments identified. The decisive factor is the debt gate: interest-bearing debt of ~C$76.3M (borrowings C$38.7M plus lease liabilities C$37.7M at June 30, 2026) is ~36.1% of a ~C$211.7M market cap, over the ~33% AAOIFI ceiling. Interest income is ~0.06% of revenue (passes); cash of ~C$9.6M is ~4.5% of market cap (passes).
Why does CareRx fail the debt screen?
At June 30, 2026 CareRx carried C$38.7M of borrowings (term loan and other) and C$37.7M of lease liabilities — ~C$76.3M of interest-bearing debt in total. Against ~65,551,613 fully diluted shares at C$3.23 (~C$211.7M market cap, October 1, 2026), that is ~36.1%. Note the sensitivity: borrowings alone are only ~18.3% of market cap, so the FAIL hinges on counting lease liabilities as debt, consistent with our methodology across all screeners.
Do CareRx's other ratios pass?
Yes. Interest income is a separately disclosed line: ~C$112k for the six months ended June 30, 2026, roughly ~C$224k annualized against ~C$375M of annualized revenue — about 0.06%, far under the ~5% ceiling. Cash and cash equivalents of ~C$9.6M (restricted cash of ~C$0.5M excluded; no short-term securities line) are ~4.5% of market cap, well under the ~33% cash-plus-securities ceiling. Only the debt gate fails.
What do Zoya, Musaffa and ShariaPortfolio say about CareRx?
As of October 1, 2026: Zoya's screening data is app-gated and we found no public CRRX page, so Zoya coverage cannot be confirmed or denied; Musaffa publishes per-stock pages for TSX tickers but musaffa.com/stock/CRRX.CA/ returns a 404 and site search returns zero results, so Musaffa does not cover it; ShariaPortfolio has no public per-stock screener database. Our screener reports its own figure-by-figure analysis above.
Could CareRx become halal?
The FAIL is close — 36.1% against a ~33% ceiling — so paying down the term loan or lease liabilities, or share-price appreciation against the ~C$211.7M market cap, could flip the result. Only the debt gate fails; the business, interest income and cash all pass. Re-screen quarterly after earnings.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).